NASDAQ:SPRB

Spruce Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy SPRB

*Your capital is at risk

$42.83

-0.540 (-1.25%)

At Close: Jul 31, 2026

Spruce Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -11.35. In total, the insiders bought 146.94K and sold 31.93K SPRB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-11.35
● Buy	146.94K shares
● Sell	31.93K shares
65% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Jul 27, 2026 Analysis Breakdown: Weakened by a contradictory negative Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Simpson Camilla V Director	Director	173 Value: $18.7K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Spiegelman Daniel K Director	Director	88 Value: $9K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Spiegelman Daniel K Director	Director	400 Value: $41.7K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Spiegelman Daniel K Director	Director	458 Value: $47.7K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Gharib Samir M. President And CFO	CEO / President	953 Value: $219.4K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Gharib Samir M. President And CFO	CEO / President	733 Value: $1.10M
Dec 11, 2025 Buy	Employee Stock Option (right to buy) A-Award	Szwarcberg Javier B. Chief Executive Officer	CEO / President	10 000 Value: $1.04M
Dec 11, 2025 Sell	Employee Stock Option (right to buy) D-Return	Szwarcberg Javier B. Chief Executive Officer	CEO / President	10 000 Value: $3.44M
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Camilla V Director	Director	400 Value: $41.7K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Camilla V Director	Director	362 Value: $37.7K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Camilla V Director	Director	309 Value: $32.2K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Simpson Camilla V Director	Director	173 Value: $18.0K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Simpson Camilla V Director	Director	133 Value: $13.8K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Simpson Camilla V Director	Director	309 Value: $38.0K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Simpson Camilla V Director	Director	362 Value: $83.4K
Dec 11, 2025 Sell	Stock Option (right to buy) D-Return	Simpson Camilla V Director	Director	133 Value: $152.0K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Simpson Camilla V Director	Director	400 Value: $67.8K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Barretto-ko Percival Director	Director	800 Value: $135.6K
Dec 11, 2025 Buy	Common Stock J-Other	Walbert Keli Insider	Other	0 Value: $0
Dec 11, 2025 Sell	Stock Option (right to buy) D-Return	Spiegelman Daniel K Director	Director	88 Value: $100.6K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Grey Michael G Executive Chairman	CEO / President	1 499 Value: $156.1K
Dec 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Grey Michael G Executive Chairman	CEO / President	666 Value: $69.4K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Grey Michael G Executive Chairman	CEO / President	133 Value: $13.8K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Grey Michael G Executive Chairman	CEO / President	387 Value: $41.8K
Dec 11, 2025 Sell	Stock Option (Right to Buy) D-Return	Grey Michael G Executive Chairman	CEO / President	1 499 Value: $345.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SPRUCE BIOSCIENCES, INC.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adu...

Read Full Profile Here